Aligning Regulatory Approach with Commercial Needs

AI SummaryClose X

CelLBxHealth plc is discontinuing the maintenance of its FDA establishment license and device listing for the Parsortix system to align with current commercial needs and strengthen cost discipline, as over 97% of platforms are used for research where the listing offers no commercial benefit. This strategic adjustment allows the company to reallocate resources towards revenue growth, customer support, and product development, while retaining the flexibility to reinstate the listing if advantageous. The decision has no impact on sales pipelines, market forecasts, customer support, or ongoing partnerships.

Disclaimer*

UK 100

Latest directors dealings